Menu
Back to Journals » Drug Design, Development and Therapy » Volume 4 » default
Drug Design, Development and Therapy
ISSN: 1177-8881
- View all (3975)
- Volume 17, 2023 (219)
- Volume 16, 2022 (316)
- Volume 15, 2021 (399)
- Volume 14, 2020 (477)
- Volume 13, 2019 (387)
- Volume 12, 2018 (382)
- Volume 11, 2017 (330)
- Volume 10, 2016 (374)
- Volume 9, 2015 (543)
- Volume 8, 2014 (231)
- Volume 7, 2013 (143)
- Volume 6, 2012 (42)
- Volume 5, 2011 (40)
- Volume 4, 2010 (35)
- Volume 3, 2009 (27)
- Volume 2, 2008 (29)
- Volume 1, 2007 (1)
Archive: Volume 4, 2010
Corrigendum: Chimeric design, synthesis, and biological assays of a new nonpeptide insulin-mimetic vanadium compound to inhibit protein tyrosine phosphatase 1B
Scior T, Guevara-Garcia JA, Melendez FJ, et al
Drug Design, Development and Therapy 2010, 4:415-416
Published Date: 13 December 2010
Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease – a perspective
Richard Kones
Drug Design, Development and Therapy 2010, 4:383-413
Published Date: 9 December 2010
Profile of belatacept and its potential role in prevention of graft rejection following renal transplantation
Gaurav Gupta, Karl L Womer
Drug Design, Development and Therapy 2010, 4:375-382
Published Date: 1 December 2010
Comparative bioequivalence studies of tramadol hydrochloride sustained-release 200 mg tablets
Suhas S Khandave, Satish V Sawant, Santosh S Joshi, et al
Drug Design, Development and Therapy 2010, 4:367-374
Published Date: 25 November 2010
New approaches in the management of multiple sclerosis
Laurie J Barten, Douglas R Allington, Kendra A Procacci, et al
Drug Design, Development and Therapy 2010, 4:343-366
Published Date: 24 November 2010
Adjunctive therapy for the treatment of primary generalized tonic-clonic seizures: focus on once-daily lamotrigine
Linda Steinbaugh, Jerzy P Szaflarski
Drug Design, Development and Therapy 2010, 4:337-342
Published Date: 18 November 2010
Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass
Ronald C Hamdy
Drug Design, Development and Therapy 2010, 4:321-335
Published Date: 18 November 2010
A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patients
Mark Kowalski, Joycelyn Entwistle, Jeannick Cizeau, et al
Drug Design, Development and Therapy 2010, 4:313-320
Published Date: 15 November 2010
Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections
Emily Zoller, Connie Valente, Kyle Baker, et al
Drug Design, Development and Therapy 2010, 4:299-311
Published Date: 4 November 2010
Silodosin in the treatment of benign prostatic hyperplasia
Maxime Rossi, Thierry Roumeguère
Drug Design, Development and Therapy 2010, 4:291-297
Published Date: 27 October 2010
Liraglutide in the management of type 2 diabetes
Estela Wajcberg, Amatur Amarah
Drug Design, Development and Therapy 2010, 4:279-290
Published Date: 22 October 2010
Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy
Aarat M Patel, Larry W Moreland
Drug Design, Development and Therapy 2010, 4:263-278
Published Date: 1 October 2010
Thermosensitive Pluronic® hydrogel: prolonged injectable formulation for drug abuse
Katayoun Derakhshandeh, Mahtab Fashi, Seyedalireza Seifoleslami
Drug Design, Development and Therapy 2010, 4:255-262
Published Date: 20 September 2010
Current and developing therapeutic agents in the treatment of Chagas disease
Werner Apt
Drug Design, Development and Therapy 2010, 4:243-253
Published Date: 17 September 2010
Chimeric design, synthesis, and biological assays of a new nonpeptide insulin-mimetic vanadium compound to inhibit protein tyrosine phosphatase 1B
Thomas Scior, José Antonio Guevara-García, FJ Melendez, et al
Drug Design, Development and Therapy 2010, 4:231-242
Published Date: 23 September 2010
Safety and efficacy of azacitidine in myelodysplastic syndromes
Carlos E Vigil, Taida Martin-Santos, Guillermo Garcia-Manero
Drug Design, Development and Therapy 2010, 4:221-229
Published Date: 9 September 2010
Antithrombotic strategies in patients undergoing percutaneous coronary intervention for acute coronary syndrome
Son V Pham, Phuong-Chi T Pham, Phuong-Mai T Pham, et al.
Drug Design, Development and Therapy 2010, 4:203-220
Published Date: 6 September 2010
Emerging treatments in the management of schizophrenia – focus on sertindole
Maria Rosaria A Muscatello, Antonio Bruno, Gianluca Pandolfo, et al
Drug Design, Development and Therapy 2010, 4:187-201
Published Date: 24 August 2010
Development of QSAR model for immunomodulatory activity of natural coumarinolignoids
Dharmendra K Yadav, Abha Meena, Ankit Srivastava, et al
Drug Design, Development and Therapy 2010, 4:173-186
Published Date: 30 July 2010
A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy
Samuel L Washington III, Alan W Shindel
Drug Design, Development and Therapy 2010, 4:159-171
Published Date: 4 August 2010
Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD
Mark A Giembycz, Stephen K Field
Drug Design, Development and Therapy 2010, 4:147-158
Published Date: 14 July 2010
Eltrombopag – a novel approach for the treatment of chronic immune thrombocytopenic purpura: review and safety considerations
Lucy Cook, Nichola Cooper
Drug Design, Development and Therapy 2010, 4:139-145
Published Date: 29 June 2010
Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients
John Puetz
Drug Design, Development and Therapy 2010, 4:127-137
Published Date: 28 June 2010
Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine
Clemens Warnke, Heinz Wiendl, Hans-Peter Hartung, et al
Drug Design, Development and Therapy 2010, 4:117-126
Published Date: 18 June 2010
Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders
Pär I Johansson, Sisse R Ostrowski
Drug Design, Development and Therapy 2010, 4:107-116
Published Date: 29 June 2010
Development of a sublingual allergy vaccine for grass pollinosis
Franco Frati, Silvia Scurati, Paola Puccinelli, et al
Drug Design, Development and Therapy 2010, 4:99-105
Published Date: 17 June 2010
Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)
M Tiseo, M Bartolotti, F Gelsomino, et al
Drug Design, Development and Therapy 2010, 4:81-98
Published Date: 19 May 2010
ACAM2000™: The new smallpox vaccine for United States Strategic National Stockpile
Aysegul Nalca, Elizabeth E Zumbrun
Drug Design, Development and Therapy 2010, 4:71-79
Published Date: 17 May 2010
Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension
Gautam V Ramani, Myung H Park
Drug Design, Development and Therapy 2010, 4:61-70
Published Date: 6 May 2010
New anticoagulants for the prevention of venous thromboembolism
Cecilia Becattini, Alessandra Lignani, Giancarlo Agnelli
Drug Design, Development and Therapy 2010, 4:49-60
Published Date: 7 April 2010
New atypical antipsychotics for schizophrenia: iloperidone
Silvio Caccia, Luca Pasina, Alessandro Nobili
Drug Design, Development and Therapy 2010, 4:33-48
Published Date: 15 February 2010
Continuation treatment of major depressive disorder: is there a case for duloxetine?
Trevor R Norman, James S Olver
Drug Design, Development and Therapy 2010, 4:19-31
Published Date: 12 February 2010
Sumatriptan-naproxen fixed combination for acute treatment of migraine: a critical appraisal
Chaouki K Khoury, James R Couch
Drug Design, Development and Therapy 2010, 4:9-17
Published Date: 25 January 2010
Corrigendum
Nusrat Motlekar, Bi-Botti Youan
Drug Design, Development and Therapy 2010, 4:7-8
Published Date: 26 January 2010
Recent advances in the treatment of premature ejaculation
Kate D Linton, Kevan R Wylie
Drug Design, Development and Therapy 2010, 4:1-6
Published Date: 5 January 2010